Cargando…

Attenuating hyperinflammation in COVID-19: A change in paradigm?

Detalles Bibliográficos
Autores principales:	Molnar, Zsolt, Bakker, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375956/ https://www.ncbi.nlm.nih.gov/pubmed/32741525 http://dx.doi.org/10.1016/j.jcrc.2020.07.015

Ejemplares similares

Immunopathology of Hyperinflammation in COVID-19
por: Gustine, Joshua N., et al.
Publicado: (2021)

The Role of Butyrate in Attenuating Pathobiont-Induced Hyperinflammation
por: Chen, Jiezhong, et al.
Publicado: (2020)

In Situ Neutralization and Detoxification of LPS to Attenuate Hyperinflammation
por: Li, Xiaoyu, et al.
Publicado: (2023)

Management of hyperinflammation in COVID-19 patients
por: Suberviola, Borja, et al.
Publicado: (2022)

Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity?
por: Taha, Sara Ibrahim, et al.
Publicado: (2022)

A nanotrap improves survival in severe sepsis by attenuating hyperinflammation
por: Shi, Changying, et al.
Publicado: (2020)

COVID-19 Hyperinflammation: What about Neutrophils?
por: Didangelos, Athanasios
Publicado: (2020)

Frontal encephalopathy related to hyperinflammation in COVID-19
por: Cani, Ilaria, et al.
Publicado: (2020)

Delving beneath the surface of hyperinflammation in COVID-19
por: Reddy, Kiran, et al.
Publicado: (2020)

Hyperinflammation with COVID-19: The key to patient deterioration?()()
por: Haigh, Kathryn, et al.
Publicado: (2020)

Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19
por: Tanner, Tamara, et al.
Publicado: (2020)

IgGs drive COVID-19 myeloid hyperinflammation
por: Park, Matthew D.
Publicado: (2020)

ACEi reduces hypertension-induced hyperinflammation in COVID-19
por: Lim, Gregory B.
Publicado: (2021)

Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
por: Ritchie, Andrew I, et al.
Publicado: (2020)

The role of ibrutinib in COVID-19 hyperinflammation: A case report
por: Maynard, Suzanne, et al.
Publicado: (2021)

Hyperinflammation, T cells, and endotoxemia
por: Inoue, Makoto, et al.
Publicado: (2015)

COVID‐19: lambda interferon against viral load and hyperinflammation
por: Andreakos, Evangelos, et al.
Publicado: (2020)

Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist
por: Papadopoulou, Charalampia, et al.
Publicado: (2020)

Altered Cholesterol and Lipid Synthesis Mediates Hyperinflammation in COVID-19
por: Sohrabi, Yahya, et al.
Publicado: (2021)

COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
por: TUFAN, Abdurrahman, et al.
Publicado: (2020)

Neutrophil Extracellular Traps Contribute to COVID-19 Hyperinflammation and Humoral Autoimmunity
por: Torres-Ruiz, Jiram, et al.
Publicado: (2021)

A brewing storm: The neuropsychological sequelae of hyperinflammation due to COVID-19
por: Cothran, Thomas P., et al.
Publicado: (2020)

In Situ Neutralization and Detoxification of LPS to Attenuate Hyperinflammation (Adv. Sci. 26/2023)
por: Li, Xiaoyu, et al.
Publicado: (2023)

COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps
por: Borges, Leandro, et al.
Publicado: (2020)

Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19
por: Smeets, Tim J. L., et al.
Publicado: (2022)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
por: Salvatierra, Juan, et al.
Publicado: (2021)

Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
por: Bonaventura, Aldo, et al.
Publicado: (2022)

Early experience with anti-interleukin-6 therapy in COVID-19 hyperinflammation
por: Marwah, Vikas, et al.
Publicado: (2021)

Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors
por: Gasparyan, Armen Yuri, et al.
Publicado: (2022)

Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation
por: TUFAN, Abdurrahman, et al.
Publicado: (2021)

Metabolic modeling of single bronchoalveolar macrophages reveals regulators of hyperinflammation in COVID-19
por: Zhao, Qiuchen, et al.
Publicado: (2022)

Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series
por: Clark, Kristina E N, et al.
Publicado: (2020)

A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling
por: Hasan, Djo, et al.
Publicado: (2021)

Blood Hyperviscosity: A Novel Link Between Hyperinflammation and Hypercoagulability in COVID-19
por: Bonaventura, Aldo, et al.
Publicado: (2022)

High-dose intravenous vitamin C attenuates hyperinflammation in severe coronavirus disease 2019
por: Xia, Guozhi, et al.
Publicado: (2021)

Network Pharmacology Reveals That Resveratrol Can Alleviate COVID-19-Related Hyperinflammation
por: Xiao, Zijian, et al.
Publicado: (2021)

Inhibition of the mitochondrial pyruvate carrier simultaneously mitigates hyperinflammation and hyperglycemia in COVID-19
por: Zhu, Bibo, et al.
Publicado: (2023)

Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19
por: Zaid, Younes, et al.
Publicado: (2021)

P1542: RUXOLITINIB IN COVID-19 PATIENTS WITH DEFINED HYPERINFLAMMATION: THE RUXCOFLAM TRIAL
por: Birndt, Sebastian, et al.
Publicado: (2023)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tr2cglee2tc4e7c1knjaqbntn2